The Pharma Data

OCTOBER 14, 2020

Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. The study led by Dr. Sergei Rudchenko, Ph.D., 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

The Pharma Data

NOVEMBER 29, 2020

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. no CMV disease (compared to 2 out of 14 cases in the placebo group).

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

The Pharma Data

JUNE 7, 2023

Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Therapies 40

Therapies RNA Licensing Licensing 40

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. Companies enter into exclusive license and co-development agreement to accelerate global reach of Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor for the treatment of HER-2 positive cancers. Non-GAAP EPS of $1.74

Vaccine 40

Vaccine Trials Treatment Therapies 40

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. based Horizon Discovery Group granted a license to China’s Sanyou Biopharmaceuticals Co. in Mainland China.

Licensing 52

Licensing Licensing DNA Drugs 52

The Pharma Data

DECEMBER 16, 2020

AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. The goal will be to develop anti-SARS-CoV-2-specific dMAbs which could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19. Most Read Today.

Vaccine 52

Vaccine DNA Government Pharma Companies 52